Age Related Eye Disease Study 2
AREDS2 started in 2006 and just as in the original AREDS trial, involved more than 4,000 participants. Over the next 5-6 years it looked into whether other ingredients could improve the original AREDS formulation.
Specifically they were looking into the effect of adding lutein and zeaxanthin (two carotenoids from plant sources) and EPA/DHA (omega 3 fatty acids such as those found in oily fish). The trial also tested the effect of omitting the beta-carotene and lowering the zinc levels (as these can cause side effects in some people).
The AREDS2 researchers measured the progression to advanced AMD by examining images of the back of the eye for yellow deposits called drusen or by commencing treatment for advanced AMD.
The results were announced during a Special Session at ARVO (Association for Research in Vision and Ophthalmology) on May 5th 2013.
These new results led the researchers to change the recommended formula, excluding beta-carotene (vitamin A) and including lutein and zeaxanthin as follows:
The risk of developing advanced macular degeneration was reduced by at least a further 25% (over the original AREDS results) in those who took this formulation in a clinical trial.
As a result, UK ophthalmologists in hospital eye clinics are now recommending this formula available as our Viteyes 2 capsules.